FBL and systemic sclerosis: Optimally this future study would include a large SSc cohort supported by detailed background clinical characteristics and an expanded autoantibody profile to include the addition of other SSC-specific autoantibody targets [12], such as Cenp-B, fibrillarin, U1 RNP, NOR 90, Th/To, U11/U12 RNP, PDGFR, and Ku.